Company / Capital Expenditures
Jazz Pharmaceuticals Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$58.8M
FY2025
5-year range
$15.0M / $58.8M
FY2021-FY2025
Trend
+54.3%
vs FY2024
Sector context
#25 of 194
Health Care
What the data says
Jazz Pharmaceuticals's capital expenditures of $59M is higher than 87% of companies in the Health Care sector (FY2025). Capital Expenditures has increased for 3 consecutive years, from $15M in FY2022 to $59M in FY2025.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of +23.6%. Top quartile in the Health Care sector.
Improved from $24M to $59M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +57.6%
- 5-Year CAGR
- +23.6%
- 10-Year CAGR
- -
Sector benchmark
-50.0% below sector average
Key checks
Key Insights
- Jazz Pharmaceuticals's capital expenditures has grown for 3 consecutive years.
- 5-year CAGR of +23.6%, indicating consistent growth.
- In FY2025, capital expenditures increased 54.3% year-over-year.
- Ranks #25 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.8M | +54.3% |
| FY2024 | $38.1M | +58.9% |
| FY2023 | $24.0M | +59.7% |
| FY2022 | $15.0M | -62.6% |
| FY2021 | $40.1M | +97.0% |
| FY2020 | $20.4M | -29.6% |
| FY2019 | $28.9M | +198.9% |
| FY2018 | $9.7M | -66.5% |
| FY2017 | $28.9M | -20.4% |
| FY2016 | $36.3M | +1.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026